Home Therapy with Plasma-Derived C1 Inhibitor: A Strategy to Improve Clinical Outcomes and Costs in Hereditary Angioedema

Publisher： Karger

E-ISSN： 1423-0097|166|4|259-266

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.166, Iss.4, 2015-04, pp. : 259-266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of plasma‐derived C1‐esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1552-1561

John Wiley & Sons Inc

Access to resources Recommend Favorite

Plasma‐derived C1‐INH for managing hereditary angioedema in pediatric patients: A systematic review

By  

PEDIATRIC ALLERGY AND IMMUNOLOGY, Vol. 26, Iss. 6, 2015-09 ,pp. : 537-544

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

By  

ALLERGY, Vol. 105-4538, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

By  

ALLERGY, Vol. 70, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Prophylaxis of Hereditary Angioedema with a Pasteurized C1 Inhibitor Concentrate

By  

International Archives of Allergy and Immunology, Vol. 154, Iss. 4, 2010-10 ,pp. : 356-359

Karger

Access to resources Recommend Favorite